AxoGen (AXGN) FY Conference June 11, 2025 02:00 PM ET Speaker0 All good? All right. Well, to everyone who was here today to learn a little bit about AxoGen. Just before I get started, just want to draw everyone's attention to our forward looking statements. You're familiar with these and we will certainly be making forward looking statements but we may or may not be updating these on a regular basis. So, little bit about me. My name is Mike Dale. I've been, as you can tell by my gray hair, around for a litt ...

ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale, board director, chief executive officer, and president, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference, on Wednesday, June 11, 2025, at 2:00 p.m. ET. Webcast events can be accessed live through the Investors page at www.axogeninc.com. For t ...

A downtrend has been apparent in AxoGen (AXGN) lately with too much selling pressure. The stock has declined 25% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Exact Name of Registrant as Specified in Its Charter) Minnesota (State or other ...

AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this regenerative medicine company would post earnings of $0.04 per share when it actually produced earnings of $0.08, delivering a surprise of 100%.Over the last four quarters, the compan ...

AxoGen (AXGN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Michael Dale - President, CEO & Board DirectorNir Naor - Chief Financial OfficerJens Schroeder Kemp - Chief Marketing OfficerCaitlin Cronin - DirectorChris Pasquale - Partner - Medical Devices & SuppliesBrett Gasaway - VP - Equity ResearchMatthew Park - Equity Research AssociateRick Ditto - VP, Global Health Economics, Reimbursement & PolicyJayson Bedford - Managing Director - Medical Technology Conference Call Participants Mi ...

AxoGen (AXGN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director Nir Naor, Chief Financial Officer and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter twenty twenty five financial results and corporate highlights. Nir will then provide an analysis of our financial performance and guidance and discuss our outlook for the year, followed by a question and answer session. ...

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement"), effective as of May 12, 2025 (the "Effective Date"), is made by and between AXOGEN CORPORATION, a Delaware corporation ("AXOGEN"), and Lindsey Hartley ("Employee") (collectively, the "Parties"). RECITALS: WHEREAS, AXOGEN and the Employee desire to enter into this Agreement to state the terms and conditions of the Agreement in its entirety on the Effective Date on the terms and conditions set forth in this Agreement. NOW, THEREFORE, in consideration of t ...

ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first ...

Lindsey Hartley, CPA, appointed as Chief Financial Officer to succeed Nir NaorALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to ...